Opdivo (nivolumab) plus chemotherapy show statistically significant improvement in pathologic complete response as neoadjuvant treatment of resectable non-small cell lung cancer in phase 3 CheckMate-816 trial
CheckMate –816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery Positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy versus chemotherapy as neoadjuvant therapy in a